Christian Leikert

inContAlert is a MedTech start-up in the field of incontinence. We are passionate about helping people with bladder dysfunction in their daily life. Our solution consists of a wearable sensor system for measuring the filling level of the urinary bladder, which sends an alert to incontinence patients when a predefined filling level is reached. inContAlert thereby minimizes the risk of an uncontrolled loss of urine and empowers patients to live a normal and jaunty life.

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

vasopharm is dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences.

vasopharm is dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences.

Working to solve chronic sinusitis

AYOXXA - The translational proteomics company AYOXXA Biosystems GmbH, based in Cologne (Germany), is an international biotech company focused on the development of its proprietary beads-on-a-chip technology for advanced protein analysis. LUNARIS™. AYOXXA’s innovative multiplex protein analysis platform is a fully integrated system designed for the parallel analysis of multiple biomarkers in picogram amounts of biological samples, allowing scientists to gain a maximum of high quality and reproducible insights. LUNARIS™ is fully scalable, with integrated, image-based quality control and transparent data processing and management, enabling translational proteomics by addressing all the needs from basic to clinical research and development. AYOXXA is commercializing and expanding a portfolio of detection kits covering ophthalmology, model-to-man and immuno-oncology applications.

Cube Biotech was founded by a team of membrane protein experts. We provide dedicated services and collaborations for membrane protein applications that facilitate structure based drug design: - Expression: in pro- and eukaryotic systems and cell-free - Purification: using standard tags and customized affinity chromatography - Crystallization: using vapour diffusion, LCP, and proprietary CIMP methods To ensure the highest quality in our service offering, we produce our own consumables. Our raw materials are sourced from selected suppliers committed to the highest quality standards. Many consumables that we use in our service are provided to the community, accompanied by dedicated protocols and handbooks, as well as tips and tricks for success. As a small, flexible company, we address your needs for standard and customized products at almost any scale. We are looking for long-term collaborations with industrial and academic partners. Contact us to learn more.

Aegis Analytical Corp. provides Discoverant, an Enterprise Manufacturing Intelligence software platform that enables manufacturers to produce regulated and specialty products more efficiently. Discoverant leverages existing IT investments and provides on-demand access, contextualization, analysis and reporting for all manufacturing, quality and process development data. Aegis’ customers maintain lean supply chains and achieve operational excellence through improved process performance and predictability, and accelerated tech transfer and process scale-up. Aegis' Discoverant goes beyond business intelligence, to enable process intelligence which provides a deeper understanding of each process and product.

GANYMED Pharmaceuticals AG is a biotechnology company based out of 12Freiligrathstraße, Mainz, Rhineland-Palatinate, Germany.

inContAlert is a MedTech start-up in the field of incontinence. We are passionate about helping people with bladder dysfunction in their daily life. Our solution consists of a wearable sensor system for measuring the filling level of the urinary bladder, which sends an alert to incontinence patients when a predefined filling level is reached. inContAlert thereby minimizes the risk of an uncontrolled loss of urine and empowers patients to live a normal and jaunty life.

CARMA FUND I is an early-stage investment fund for advancing Life Science and Healthcare technologies. The fund started off with a First Closing in June 2022 and has €50M under management. It is based in Munich and Frankfurt am Main.

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

vasopharm is dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences.

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors (AAV, Adenoviral vectors, Lentiviral vectors,), vaccines and complex recombinant proteins. With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents and cGMP plasmids. CEVEC’s CAP® Technology based on human suspension cells is the ideal production platform for RCA-free Adenoviral vectors, Lentiviral vectors, Oncolytic viruses, Viral vaccines and exosomes. With the CAP-Go® Technology CEVEC provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors and plasma proteins.